Full metadata record
DC Field | Value | Language |
---|---|---|
dc.creator | Casares, N. (Noelia) | - |
dc.creator | Lasarte, J.J. (Juan José) | - |
dc.creator | Lopez-Diaz-de-Cerio, A. (Ascensión) | - |
dc.creator | Sarobe, P. (Pablo) | - |
dc.creator | Ruiz, M. (Marta) | - |
dc.creator | Melero, I. (Ignacio) | - |
dc.creator | Prieto, J. (Jesús) | - |
dc.creator | Borras-Cuesta, F. (Francisco) | - |
dc.date.accessioned | 2012-01-15T14:55:15Z | - |
dc.date.available | 2012-01-15T14:55:15Z | - |
dc.date.issued | 2001 | - |
dc.identifier.citation | Casares N, Lasarte JJ, de Cerio AL, Sarobe P, Ruiz M, Melero I, et al. Immunization with a tumor-associated CTL epitope plus a tumor-related or unrelated Th1 helper peptide elicits protective CTL immunity. Eur J Immunol 2001 Jun;31(6):1780-1789. | es_ES |
dc.identifier.issn | 1521-4141 | - |
dc.identifier.uri | https://hdl.handle.net/10171/20412 | - |
dc.description.abstract | Immunization with cytotoxic T cell epitope SPSYVYHQF (AH1), derived from MuLV gp70 envelope protein expressed by CT26 tumor cells, does not protect BALB/c mice against challenge with CT26 tumor cells. By contrast, immunization with AH1 plus T helper peptides OVA(323-337) or SWM(106-118) eliciting Th1 and Th0 profiles, protected 83% and 33% of mice, respectively. Interestingly, immunization with AH1 plus both helper peptides reverted the efficacy to 33%. We identified the endogenous T helper peptide p(320-333) from gp70 which elicits a Th1 profile and is naturally processed. As for OVA(323-337), immunization with p(320-333) alone did not protect against tumor challenge. However, p(320-333) plus AH1 protected 89% of mice at day 10 after vaccination. Only 20% of mice vaccinated with AH1 + OVA(323-337) or AH1 + p(320-333) were protected when challenged 80 days after immunization. Treatment with OVA(323-337) or with p(320-333) around established tumors delayed tumor growth. Our results show that tumor-related as well as tumor-unrelated but strong Th1 peptides may be useful for inducing CTL responses in tumor immunotherapy. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Wiley Vch Verlag Berlin | es_ES |
dc.rights | info:eu-repo/semantics/openAccess | es_ES |
dc.subject | CTL | es_ES |
dc.subject | Th1/Th2 | es_ES |
dc.subject | Tumor immunity | es_ES |
dc.subject | Cytokine | es_ES |
dc.title | Immunization with a tumor-associated CTL epitope plus a tumor-related or unrelated Th1 helper peptide elicits protective CTL immunity | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.relation.publisherversion | http://bit.ly/s8V1T0 | es_ES |
dc.type.driver | info:eu-repo/semantics/article | es_ES |
Files in This Item:
Statistics and impact
Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.